This is a routine clinical milestone with no financial data. Monitor for preliminary efficacy results expected in late 2026 or early 2027, which will be the next major catalyst for CDI-988. No immediate trading action warranted.
Price Chart
Executive Summary
Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988 as a preventive and treatment. No serious adverse events have been reported, and preliminary efficacy results are expected in late 2026 or early 2027. This is a routine clinical milestone for a pre-revenue biotech with no financial data in the filing.
Key Facts
- Last subject dosed in Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988
- No serious adverse events reported to date
- Preliminary efficacy results expected in late 2026 or early 2027
- CDI-988 is the first oral antiviral drug candidate developed for norovirus acute gastroenteritis
- Phase 1b study is randomized, double-blind, placebo-controlled at Emory University School of Medicine
- Primary endpoint: efficacy vs placebo in reducing incidence of clinical symptoms
- CDI-988 previously demonstrated safety and tolerability in a Phase 1 study in Australia at doses up to 1200 mg
Financial Impact
No financial data provided in this filing
Risk Factors
- Clinical trial failure risk — efficacy data may not meet primary endpoint
- Pre-revenue company with no approved products and reliance on future financing
- Long timeline to potential commercialization with regulatory and competitive uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-041877 |
| Exhibit: ex99-1.htm | 0001493152-26-041877 |
| Document: 0001493152-26-041877-index-headers.html | 0001493152-26-041877 |
| Document: 0001493152-26-041877-index.html | 0001493152-26-041877 |
| Document: 0001493152-26-041877.txt | 0001493152-26-041877 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $1.24 | awaiting T+60 | — | $0.9700 (−21.77%) |
Aug 3, 2026 12w ago | 8-K | $0.9400 | awaiting T+60 | — | $0.9700 (+3.19%) |
Jun 9, 2026 19w ago | 8-K | $1.02 $1.16 | ▲ +13.73% | ▲ +9.91% | $0.9700 (−4.90%) |
Jun 3, 2026 20w ago | 8-K | $1.06 $1.14 | ▲ +7.55% | ▲ +5.05% | $0.9700 (−8.49%) |
May 27, 2026 21w ago | DEFA14A | $1.13 $1.15 | ▲ +1.77% | ▲ +0.03% | $0.9700 (−14.16%) |
May 26, 2026 21w ago | 8-K | $1.13 $1.15 | ▲ +1.33% | ▼ −1.40% | $0.9700 (−14.16%) |
May 15, 2026 23w ago | Press Release | $1.20 $1.08 | ▼ −10.00% | ▼ −14.52% | $0.9700 (−19.17%) |
May 4, 2026 25w ago | EFFECT | $1.31 $0.8703 | ▲ +33.56% | ▲ +35.42% | $0.9700 (+25.95%) |
Apr 2, 2026 29w ago | 8-K | $1.51 $1.05 | ▼ −30.46% | ▼ −44.62% | $0.9700 (−35.76%) |
Mar 31, 2026 29w ago | 8-K | $1.01 $1.02 | ▲ +0.99% | ▼ −11.39% | $0.9700 (−3.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers